Rob Stein

What's the U.S. doing to watch out for the omicron variant? Here's the work underway and the challenges that experts say may slow down the country's efforts.

Public health experts worry confusion about boosters may hamper vaccine efforts, breakthrough cases aren't being monitored, and more testing and genetic sequencing is needed to track the new variant.

By the end of the week, the Food and Drug Administration is poised to authorize the Pfizer booster for anyone age 18 and older, who is already vaccinated.

Scientists have begun to find abnormalities in the immune systems of some long-COVID patients that might help explain the syndrome, at least in some people. But there is still much more to learn.

Some experts worry "boostermania" is distracting from the goal of getting tens of millions of unvaccinated Americans their first shots.

The number of people getting boosters every day in the U.S. is more than double the number of people getting their first shot, a win for Biden's booster plan but a loss for greater vaccination goals.

The centers for Disease Control and Prevention issues recommendations for how to mix-and-match COVID-19 boosters — marking the final step for making boosters widely available.

After the FDA weighed in, advisers to the Centers for Disease Control and Prevention meet Thursday to refine guidelines for boosters for the Moderna and Johnson & Johnson COVID-19 vaccines.

The Food and Drug Administration and the Center For Disease Control and Prevention are poised to sign-off on Johnson & Johnson and Moderna booster shots this week.

FDA advisers vote unanimously on recommending that the agency authorize Moderna's COVID-19 vaccine boosters. The agency will consider Johnson & Johnson's booster authorization request on Friday.

The long-awaited study finds that people who got the J&J vaccine would benefit more from getting a Pfizer or Moderna vaccine as their booster instead of another J&J shot.

Should people who get a COVID booster get a different vaccine from their original shot? The results of a highly anticipated study suggest that in some cases the answer may be yes.

The Food and Drug Administration has released the evidence that Moderna and Johnson & Johnson tried to win authorization for boosters the agency weighs Merck's request for a drug to treat COVID-19.

Moderna and Johnson & Johnson say people who got COVID-19 vaccines should get additional doses to boost their protection against the delta variant. Both companies submitted evidence to the FDA.

For the first time, scientists are reporting they restored vision to people blinded by a rare genetic disorder by infusing the revolutionary gene-editing technique directly into cells inside the body.

In a first, doctors injected the gene-editing tool CRISPR directly into cells in patients' eyes. The experiment helped these vision-impaired patients see shapes and colors again.

If the latest projections about the delta surge are correct, life may finally start returning to normal again in coming months.

Walensky made a recommendation that CDC advisers rejected — giving a third shot to at-risk workers such as those in the health care industry. Her decision sides with what the FDA recommended.

Though infections are still sky-high, the U.S. may be turning a corner, according to a consortium of researchers who forecast the pandemic. And we may well be spared a winter surge.

With the FDA poised to authorize a Pfizer booster, a CDC advisory panel is scheduled to consider who exactly should get it. Johnson & Johnson says a booster also works for its one-shot vaccine.